These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33394527)

  • 1. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
    Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
    Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.
    Månsson A; Danielsson AK; Sjöqvist H; Glatz T; Lundin A; Wallhed Finn S
    Addict Sci Clin Pract; 2024 May; 19(1):41. PubMed ID: 38764075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.
    Karriker-Jaffe KJ; Ji J; Sundquist J; Kendler KS; Sundquist K
    Addiction; 2017 Aug; 112(8):1386-1394. PubMed ID: 28406579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review.
    Rosenstand NJ; Nielsen AS; Skøt L; Anhøj S; Nielsen DG; Højlund M; Mellentin AI
    Curr Neuropharmacol; 2024; 22(6):1129-1143. PubMed ID: 36582063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
    Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies.
    Leggio L; Falk DE; Ryan ML; Fertig J; Litten RZ
    Handb Exp Pharmacol; 2020; 258():443-462. PubMed ID: 31628604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
    Chaignot C; Zureik M; Rey G; Dray-Spira R; Coste J; Weill A
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1239-1248. PubMed ID: 30251424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
    Williams EC; Matson TE; Harris AHS
    Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
    Konstantelos N; Tourchian N; McCormack D; Lecce P; Tadrous M; Gomes T
    Drug Alcohol Depend; 2023 Jan; 242():109705. PubMed ID: 36463765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Pharmacotherapy Development: Human Clinical Studies.
    Litten RZ; Falk DE; Ryan ML; Fertig J; Leggio L
    Handb Exp Pharmacol; 2018; 248():579-613. PubMed ID: 29294197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
    Kranzler HR; Soyka M
    JAMA; 2018 Aug; 320(8):815-824. PubMed ID: 30167705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
    Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
    Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
    Burnette EM; Nieto SJ; Grodin EN; Meredith LR; Hurley B; Miotto K; Gillis AJ; Ray LA
    Drugs; 2022 Feb; 82(3):251-274. PubMed ID: 35133639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
    Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Alcohol Use Disorder.
    Kranzler HR
    Am J Psychiatry; 2023 Aug; 180(8):565-572. PubMed ID: 37525595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for alcohol use disorders - Unequal provision across sociodemographic factors and co-morbid conditions. A cohort study of the total population in Sweden.
    Wallhed Finn S; Lundin A; Sjöqvist H; Danielsson AK
    Drug Alcohol Depend; 2021 Oct; 227():108964. PubMed ID: 34518028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
    Hyland CJ; McDowell MJ; Bain PA; Huskamp HA; Busch AB
    J Subst Abuse Treat; 2023 Jan; 144():108919. PubMed ID: 36332528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
    Petrov I; Krogh J; Nordentoft M
    Ugeskr Laeger; 2011 Nov; 173(48):3103-9. PubMed ID: 22118653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.
    Oldfield BJ; McGinnis KA; Edelman EJ; Williams EC; Gordon AJ; Akgün K; Crystal S; Fiellin LE; Gaither JR; Goulet JL; Korthuis PT; Marshall BDL; Justice AC; Bryant K; Fiellin DA; Kraemer KL
    J Subst Abuse Treat; 2020 Feb; 109():14-22. PubMed ID: 31856946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder.
    Belnap MA; McManus KR; Grodin EN; Ray LA
    Pharmaceut Med; 2024 Jul; 38(4):291-302. PubMed ID: 38967906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.